GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Institutional Ownership

Pharmicell Co (XKRX:005690) Institutional Ownership : 5.00% (As of Jun. 10, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharmicell Co's institutional ownership is 5.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharmicell Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharmicell Co's Float Percentage Of Total Shares Outstanding is 0.00%.


Pharmicell Co Institutional Ownership Historical Data

The historical data trend for Pharmicell Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Institutional Ownership Chart

Pharmicell Co Historical Data

The historical data trend for Pharmicell Co can be seen below:

2023-07-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.89 7.93 7.95 6.83 5.47 5.49 5.49 5.13 5.00 5.00

Pharmicell Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Pharmicell Co (XKRX:005690) Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines